Long-term use of high-dose @entity10555 and XXXX for the treatment of @entity13702 .

@entity1 @entity410 @entity1024 @entity2228 @entity14031 @entity3173 @entity13702 @entity10555
OBJECTIVE: The objective of this study was to test the hypotheses that reduction of @entity2228 and blocking of the @entity1024 receptor channel complex would be beneficial for both @entity410 reduction and developmental progress in @entity1 with @entity13702 . METHODS: We administered @entity10555 (at doses of 500 to 750 mg/kg/day) and @entity14031 (at doses of 3.5 to 22.5 mg/kg/day) to four @entity1 with @entity13702 with follow-up of 3 months to 6 years. RESULTS: @entity10555 reduced to normal the @entity2228 concentration in plasma and substantially reduced but did not normalize the @entity2228 concentration in cerebrospinal fluid. @entity14031 was a potent anticonvulsant in some but not all @entity1 . There was remarkable interpatient variability in @entity14031 metabolism. Three @entity1 are living (ages ranging from 4 to 6 years) and are moderately to severely developmentally delayed; two are free of @entity410 . The third @entity1 , with the slowest development, had intractable @entity410 for nearly a month before diagnosis, and although @entity410 -free for 30 months, now has @entity3173 . One @entity1 died of intractable @entity410 at 3 months. CONCLUSIONS: These outcomes suggest that @entity10555 and @entity14031 are not uniformly effective in @entity13702 , but for some @entity1 they improve arousal, decrease or eliminate @entity410 , and allow for some developmental progress. Trials with additional @entity1 and other receptor channel blockers are warranted.
